J&J’s Prostate Cancer Drug Zytiga Approved for Earlier Use in EU

By Brian Orelli

On Friday, Johnson & Johnson‘s (NYSE: JNJ  ) Zytigareceived an expanded approval from the European Commission. The drug was previously approved for patients with metastatic castration-resistant prostate cancer who have failed a chemotherapy regimen that contains Sanofi‘s (NYSE:SNY  ) Taxotere. The new approval expands the use of Zytiga into patients who have failed androgen deprivation therapy, but who aren’t appropriate for chemotherapy yet.

The European Commission’s decision is a rubber stamp on the European Medicines Agency’s Committee for Medical Products for Human Use’s decision in November to recommend the expanded marketing authorization.

The expanded approval is based on a clinical trial of more than 1,000 patients comparing Zytiga, plus prednisone/prednisolone, to placebo, plus prednisone/prednisolone. Patients in the Zytiga arm had a statistically-significant improvement in radiographic progression-free survival, a measure of how quickly a tumor begins to grow. Treatment with Zytiga also produced longer overall survival, although the trial was stopped early, so the difference didn’t reach statistical significance.

Share This Post

Recent Articles

Leave a Reply

© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS